A Phase 2b clinical trial presented at the Alzheimer’s Association International Conference (AAIC) 2024 reveals that Novo Nordisk A/S’s (NYSE:NVO) older generation GLP-1 drug, liraglutide, may slow cognitive decline by protecting the brain. Related: Novo Nordisk’s Ozempic Reduces Smoking-Related Health Interventions In Diabetic Patients, Study Finds. GLP-1 (Glucagon-Like Peptide-1) drugs are a class of medications primarily used to treat type 2 diabetes and, in some cases, obesity. GLP-1 receptor agonists mimic the natural hormone glucagon-like peptide and help manage diabetes, promote weight loss, and reduce heart disease, stroke, and kidney disease risks. Animal studies indicate these drugs may also have neuroprotective effects, reducing ...